Friday , April 26 2024
Home / Mike Norman Economics / Puzzling higher AstraZeneca vaccine efficacy for smaller dosage explained: It was reportedly tested on people only under 56

Puzzling higher AstraZeneca vaccine efficacy for smaller dosage explained: It was reportedly tested on people only under 56

Summary:
A seemingly strange phenomenon of a smaller dose of the Oxford-AstraZeneca Covid-19 vaccine being more effective than a bigger one is reportedly explained by it first being tested on a younger group.RTPuzzling higher AstraZeneca vaccine efficacy for smaller dosage explained: It was reportedly tested on people only under 56

Topics:
Mike Norman considers the following as important:

This could be interesting, too:

John Quiggin writes The war to end war, still going on

New Economics Foundation writes Reclaiming our regions

New Economics Foundation writes New Economics Podcast: Why is the benefits system failing disabled people

Michael Hudson writes Jill Stein: Splitting the Pro-Imperial Vote

 A seemingly strange phenomenon of a smaller dose of the Oxford-AstraZeneca Covid-19 vaccine being more effective than a bigger one is reportedly explained by it first being tested on a younger group.

RT

Puzzling higher AstraZeneca vaccine efficacy for smaller dosage explained: It was reportedly tested on people only under 56

Mike Norman
Mike Norman is an economist and veteran trader whose career has spanned over 30 years on Wall Street. He is a former member and trader on the CME, NYMEX, COMEX and NYFE and he managed money for one of the largest hedge funds and ran a prop trading desk for Credit Suisse.

Leave a Reply

Your email address will not be published. Required fields are marked *